PALI
Palisade Bio Inc (PALI)
Healthcare • NASDAQ • $1.80-9.55%
- Symbol
- PALI
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.80
- Daily Change
- -9.55%
- Market Cap
- $301.72M
- Trailing P/E
- N/A
- Forward P/E
- -8.18
- 52W High
- $2.86
- 52W Low
- $0.53
- Analyst Target
- $9.71
- Dividend Yield
- N/A
- Beta
- 1.53
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The co…
Company websiteResearch PALI on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.